Watch InMed’s presentation at the Emerging Growth conference, now available on demand.
InMed’s CEO Eric A. Adams presented at Emerging Growth Conference 72 on June 13, 2024. His presentation included an update on the progress of the company’s pharmaceutical programs, including preclinical programs Alzheimer’s disease and age-related macular degeneration.
Also available to watch directly in Youtube.
Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,
A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields